MMSD
MMSD (Molecular MS Diagnostics) is a boutique contract research organization providing analytical, bioanalytical, and strategic product development services to pharmaceutical, generic drug, and biotechnology firms from its ISO 9001:2015-certified, FDA-inspected, DEA-registered laboratory in Warwick, Rhode Island.
- Company typePrivate
- Founded2007
- HeadquartersWarwick, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What MMSD does
Molecular MS Diagnostics (MMSD) is a boutique contract research organization providing analytical, bioanalytical, and strategic product development services to the life sciences industry. Established in 2007, the company operates from a 10,000-square-foot facility in Warwick, Rhode Island, housing three specialized laboratories: GMP Analytical, R&D Bioanalytical, and Cell Culture. MMSD serves pharmaceutical companies, generic drug manufacturers, and biotechnology companies, addressing their need for cost-effective analytical capacity and regulated testing without the capital expenditure of in-house laboratory infrastructure. The legal entity is Molecular MS Diagnostics, LLC, domiciled in Rhode Island.
MMSD's service portfolio spans four primary categories. Analytical Services include assay and impurity HPLC testing, method development, verification and validation, method transfer, photostability testing, dissolution testing, residual solvents analysis (headspace-GC-FID/GC-MS), impurity identification (LC-MS), and heavy metals analysis via ICP-MS. Bioanalytical Services cover plasma and urine drug analysis for small molecules, peptides, and proteins; LC-MS/MS method development; pharmacokinetic profiling (PK parameters, ADME); plasma protein binding screens; P450 screens; hepatocyte induction assays; and tissue analysis. Strategic Product Development provides drug-excipient compatibility, permeation testing, solubility, solid-state characterization, and polymorph screening. Additional offerings include Cell Culture (BioSafety Hood Level II, ELISA, peptide mapping, amino acid analysis, SEC-HPLC-MS/MS, IgG analysis, deformulation, large molecule testing), Counterfeit Drug Analysis, and Extractable and Leachable Testing. The technology stack is anchored on Waters HPLC-2695 with Empower III data acquisition, Sciex 4000Qtrap triple quadrupole mass spectrometers, Agilent ICP-MS for elemental impurities per USP <232>/<233>, UPLC with FL/PDA/MS detection, Agilent 5890 GC with headspace and FID for residual solvents per USP <467>, a Caron photostability chamber with quinine actinometry for ICH Q1B testing, and ICH-controlled stability chambers at 25C/60%RH, 30C/60%RH, and 40C/75%RH.
MMSD operates a project-based contract research revenue model with custom pricing determined by scope, methodology, and turnaround. Sales are conducted through direct enterprise engagement using a single point of contact, with service initiation via downloadable sample submission forms. Pricing is quote-based, billed under project and multi-year contract cadences, and not publicly disclosed. The company is ISO 9001:2015 certified, FDA inspected (GMP compliance), and DEA registered for Class II–V controlled substances, with SOPs, IQ/OQ/PQ documentation, automated environmental monitoring, and a QA-reviewed sample management system. Operations are concentrated in the Northeastern United States. Source data shows no disclosed funding rounds, M&A activity, partnerships, institutional ownership, or geographic expansion beyond the Northeastern US region.
MMSD firmographics
Firmographics- Name
- MMSD
- Legal name
- Molecular MS Diagnostics, LLC
- Website
- https://mmsdiagnostics.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- MMSD (Molecular MS Diagnostics) is a boutique contract research organization providing analytical, bioanalytical, and strategic product development services to pharmaceutical, generic drug, and biotechnology firms from its ISO 9001:2015-certified, FDA-inspected, DEA-registered laboratory in Warwick, Rhode Island.
- Ownership category
- akta.pro rank
MMSD industry classification
Industry- Product category
- Pharmaceutical Contract Research Services
- NAICS
- Scientific Research and Development Services (5417), Medical Laboratories (621511)
- SIC
- Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN)
Keywords
Where MMSD is headquartered
LocationHeadquarters
- HQ city
- Warwick
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
MMSD business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Contract Research Services: MMSD generates revenue through providing analytical and bioanalytical contract research services to pharmaceutical and life sciences companies. Services include method development, validation, testing, and stability studies billed on a project basis.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing for analytical and bioanalytical services |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
MMSD product offering
Product offeringCore offering
MMSD is a contract research organization providing analytical, bioanalytical, and strategic product development services to pharmaceutical and life sciences companies. Its offerings span assay and impurity HPLC testing, method development and validation, LC-MS/MS bioanalytical assays for plasma and urine, stability testing under ICH conditions, photostability, dissolution testing, residual solvents, heavy metals analysis, cell culture, and counterfeit drug analysis, delivered from an FDA-inspected, ISO 9001:2015 certified, DEA-registered laboratory in Warwick, Rhode Island.
Product overview
MMSD (Molecular MS Diagnostics) offers a portfolio of laboratory R&D services for the life sciences industry, organized around three core service lines: Analytical Services (HPLC testing, method development, photostability, dissolution, residual solvents, heavy metals, chiral analysis), Bioanalytical Services (plasma/urine analysis, LC-MS/MS, pharmacokinetic profiling, metabolite identification), and Strategic Product Development (pre-formulation, stability testing, de-formulation). Additional specialized services include Cell Culture, Counterfeit Drug Analysis, and Extractable and Leachable Testing. The company operates as a boutique CRO providing both GLP and non-GLP analytical support, with GMP-compliant testing capabilities.
Differentiator
Problem solved
Functional benefit
Products and services
- Analytical Services Assay and impurity HPLC testing for drug substance and drug products, including method development, verification/validation, method transfer, photostability testing, dissolution testing, residual solvents analysis, ICP-MS heavy metals, FTIR, UV/VIS, Karl Fisher water analysis, and chiral analysis, offered to pharmaceutical companies.
- Bioanalytical Services Plasma/blood stability assays; plasma and urine analysis of generic drugs and novel chemical entities (NCEs); LC-MS/MS method development, verification/validation, and method transfer; ADME profiling, pharmacokinetic testing, plasma protein binding screens, hepatocyte induction assays, P450 screens, in-vivo plasma analysis, and tissue analysis, provided to pharmaceutical and biotech clients.
- Strategic Product Development Provides accurate knowledge of unmet need in the product market, planning and management of product development, and effective management of resources and tools, including drug-excipient compatibility, permeation testing, solubility testing and enhancement, solid state characterization, polymorph screening, and photostability testing.
- Cell Culture Services Biosafety Hood Level II operations, ELISA testing, peptide mapping, amino acid analysis (HPLC/MS/MS), SEC-HPLC-MS/MS, IgG analysis, CEC analysis of proteins, deformulation, and large molecule testing for biotech and pharmaceutical clients.
- Stability Testing
Quantifiable outcome
- Eliminates time-consuming internal approvals and middlemen through streamlined processes
- +2 more outcomes
Companies that use MMSD
Customer profileSegments3 records
Ideal customer profiles3 records
MMSD technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
MMSD partnerships and signals
Strategic signalScale indicators4 records
Recent moves5 records
Expansion highlights3 records
MMSD competitors and assessment
Company assessmentBroad incumbents
- PPD (Thermo Fisher Scientific): Large full-service CRO now under Thermo Fisher; offers bioanalytical, central lab, and drug-development services that cover the same client engagements MMSD targets, typically at much larger scale.
- Eurofins Scientific: Global testing-services network with significant pharmaceutical analytical and bioanalytical capabilities; competes for the same pharma testing budgets as MMSD via central laboratories and CDMO-adjacent offerings.
- Charles River Laboratories: Largest publicly traded CRO offering comprehensive bioanalytical, DMPK, and stability services to pharma—directly overlapping MMSD's small-molecule and large-molecule testing work, but at vastly greater scale and global reach.
- WuXi AppTec: Global CRO/CDMO with bioanalytical and DMPK services; increasingly competes for the same small-molecule and biologics bioanalysis work that MMSD serves in the Northeastern US.
- Intertek Pharmaceutical Services: Pharmaceutical services arm of Intertek offering analytical, stability, extractables/leachables, and biopharma testing—directly comparable menu to MMSD's analytical and strategic product development offerings.
- SGS SA: Global testing, inspection, and certification company with pharmaceutical services including analytical chemistry, stability, and extractables/leachables—overlaps substantially with MMSD's compliance-driven testing menu.
Direct peers
- Pace Analytical Services: Mid-sized commercial testing laboratory operating life-sciences and pharmaceutical analytical services similar in style to MMSD, with comparable capacity, instrument footprint, and customer profile.
- EAG Laboratories: Analytical and materials testing provider for pharma and biotech—mirrors MMSD's combination of method development, impurity ID, and deformulation for drug substance and drug product.
- ABC Laboratories (now part of Curia): Mid-sized bioanalytical and analytical CRO with comparable LC-MS/MS and small-molecule testing capabilities serving pharmaceutical and generic-drug sponsors; now embedded in a larger CDMO but historically a close peer in size and scope.
- Celerion: Specialized bioanalytical and clinical pharmacology CRO closely aligned with MMSD's LC-MS/MS bioanalysis, PK profiling, and Phase I/ANDA-support work for small molecules.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
MMSD social profiles
Digital presenceMMSD compliance and trust
Trust signalCompliance3 records
MMSD financial estimates
Financial estimateRevenue estimate
Valuation estimate
MMSD leadership team
Management profileNumber of profiles
Profiles1 record
MMSD funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MMSD M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MMSD
What does MMSD do?
MMSD is a contract research organization providing analytical, bioanalytical, and strategic product development services to pharmaceutical and life sciences companies. Its offerings span assay and impurity HPLC testing, method development and validation, LC-MS/MS bioanalytical assays for plasma and urine, stability testing under ICH conditions, photostability, dissolution testing, residual solvents, heavy metals analysis, cell culture, and counterfeit drug analysis, delivered from an FDA-inspected, ISO 9001:2015 certified, DEA-registered laboratory in Warwick, Rhode Island.
Is MMSD a public or private company?
MMSD is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was MMSD founded?
MMSD was founded in 2007. It employs 1 to 10 people.
Where is MMSD based?
MMSD is headquartered in Warwick, United States, in the North America region.
How does MMSD make money?
One revenue line is on record: contract Research Services.
Who are MMSD's main competitors?
Broad incumbents on record are PPD (Thermo Fisher Scientific), Eurofins Scientific, Charles River Laboratories, WuXi AppTec, Intertek Pharmaceutical Services and SGS SA. Direct peers are Pace Analytical Services, EAG Laboratories, ABC Laboratories (now part of Curia) and Celerion.
Does MMSD have an API?
No public API is recorded for MMSD.
What industry is MMSD in?
MMSD's product category is Pharmaceutical Contract Research Services. Its primary akta.pro industry code is HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays. Its NAICS code is 5417 and its SIC code is 8734.